DUBLIN–(BUSINESS WIRE)–The “Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020” report has been added to ResearchAndMarkets.com’s offering.
The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of over 2,300 clinical stage partnering deals announced since 2014 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
The report also includes numerous tables and figures that illustrate the trends and activities in clinical stage partnering and deal making since 2014.
In addition, a comprehensive appendix of all clinical stage deals since 2014 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of clinical stage products and compounds.
Report scope
Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2020 includes:
- Trends in clinical stage dealmaking in the biopharma industry since 2014
- Analysis of clinical stage deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life clinical stage deals
- Access to over 2,300 clinical stage deals
- The leading clinical stage deals by value since 2014
- Most active clinical stage dealmakers since 2014
- The leading clinical stage partnering resources
Available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal type
- Specific therapy target
Key Topics Covered:
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Why do companies partner clinical stage compounds?
2.1. Introduction
2.2. The role of clinical stage partnering
2.2.1. In-licensing at clinical stage
2.2.2. Out-licensing at clinical stage
2.3. Difference between phase I, II and III stage deals
2.4. Reasons for entering into clinical stage partnering deals
2.4.1. Licensors reasons for entering clinical stage deals
2.4.2. Licensees reasons for entering clinical stage deals
2.5. The future of clinical stage partnering deals
Chapter 3 – Clinical stage deal strategies and structure
3.1. Introduction
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical/biotech
3.2.1.1. Discovery and preclinical stage partnering case studies
3.2.1.1.a. Case study: LEO Pharma – 4SC
3.2.1.1.b. Case study: Heptares Therapeutics – Cubist
3.2.1.1.c. Case study: Incyte – Agenus Bio
3.2.1.1.d. Case study: Janssen Pharmaceutical – Evotec
3.2.2. Partnering later in pharmaceutical/biotech
3.2.2.1. Clinical stage partnering case studies
3.2.2.1.a. Case study: Servier – GeNeuro
3.2.2.1.b. Case study: Teva – Xenon Pharmaceuticals
3.2.2.1.c. Case study: AstraZeneca – Ardelyx
3.2.2.1.d. Case study: Baxter – Onconova Therapeutics
3.3. Early and later stage partnering – a risk/cost comparison
3.4. What do companies spend on clinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure licensing agreements
3.6.1.a. Case study : Argos Therapeutics – Medinet
3.6.1.b. Case study : Pfizer – GlycoMimetics
3.7. Multicomponent clinical stage partnering agreements
3.7.1. Example multicomponent clinical stage clauses
3.7.1.a. Case study: Gilead Sciences – GlobeImmune
Chapter 4 – Clinical stage partnering payment strategies
4.1. Introduction
4.2. Clinical stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
4.3.2.1. Conditionality of upfront payments
4.3.3. Loans
4.3.4. Convertible loans
4.3.5. Equity
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
4.3.9.1. Issues affecting royalty rates
4.3.9.2. Royalties on combination products
4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech
4.3.9.3. Guaranteed minimum/maximum annual payments
4.3.9.4. Royalty stacking
4.3.9.5. Royalties and supply/purchase contracts
4.3.10. Quids
4.3.11. Option payments
Chapter 5 – Trends in clinical stage deal making
5.1. Introduction
5.2. Clinical stage partnering over the years
5.2.1. Trends in phase I deals since 2014
5.2.1.1. Attributes of phase I deals
5.2.2. Trends in phase II deals since 2014
5.2.2.2. Attributes of phase II deals
5.2.3. Trends in phase III deals since 2014
5.2.3.1. Attributes of phase III deals
5.3. Clinical stage partnering by deal type
5.4. Clinical stage partnering by disease type
5.5. Partnering by clinical stage technology type
5.6. Clinical stage partnering by most active company since 2014
Chapter 6 – Payment terms for clinical stage partnering
6.1. Introduction
6.2. Guidelines for clinical stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Clinical stage payment terms – deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Clinical stage partnering headline values
6.4.2. Clinical stage deal upfront payments
6.4.3. Clinical stage deal milestone payments
6.4.4. Clinical stage royalty rates
6.5 Clinical stage median financials
6.5.1. Clinical stage headline value
6.5.2. Clinical stage upfront value
6.5.3. Clinical stage milestone value
6.5.4. Clinical stage royalty value
Chapter 7 – Leading clinical stage deals
7.1. Introduction
7.2. Top clinical stage deals by value
Chapter 8 – Top 25 most active clinical stage dealmakers
8.1. Introduction
8.2. Top 25 most active clinical stage dealmakers
Chapter 9 – Clinical stage partnering contracts directory
9.1. Introduction
9.2. Clinical stage deals with contracts since 2014
Chapter 10 – Clinical stage deal making by development stage
10.1. Introduction
10.2. Deals by clinical stage
Phase I
Phase II
Phase III
Regulatory
Appendices
Appendix 1 – Clinical stage dealmaking by companies A-Z
Appendix 2 – Clinical stage dealmaking by industry sector
Appendix 3 – Clinical stage dealmaking by stage of development
Appendix 4 – Clinical stage dealmaking by therapy area
Appendix 5 – Clinical stage dealmaking by technology type
For more information about this report visit https://www.researchandmarkets.com/r/lvj0wh
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900